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correlate with complete remission in metastatic
breast cancer patients after sequential
immune-endocrine therapy
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Studies suggest that conventional cancer therapies given after immunotherapy (IT) can boost antitumor immunity
and possibly improve response rates and progression-free survival. We report two cases of metastatic breast cancer
with durable complete responses (CRs) after sequential IT and endocrine therapy. Immune analyses of these long-term
disease-free breast cancer patients previously treated with imiquimod (IMQ) suggest in-situ vaccination is achieved by
topical application of the TLR-7 agonist directly onto tumors. Furthermore, IT-induced antigen-specific T cells were
expanded by subsequent endocrine therapy and correlated with response, persisting > 2 years. Our findings therefore
suggest that the induction/boosting of polyfunctional tumor antigen-specific T in response to sequential immune
endocrine therapy and detected directly ex-vivo can serve as a peripheral blood biomarker for true clinical benefit.Introduction
Immunotherapy and harnessing anti-tumor immune
effects of conventional cancer therapies have great po-
tential for the treatment of several cancers. Evidence is
emerging that subtypes of breast cancer can be immuno-
genic, and that the endogenous as well as the induced
anti-tumor immune responses are linked to clinical out-
comes in breast cancer [1-6]. However, the field has
struggled to define immune monitoring benchmarks for
clinical benefit. Several studies suggest that conventional
cancer therapies given after immunotherapy, can further
boost antitumor immunity and have shown higher than
expected response rates and/or progression-free survival
[7-12]. We report on two cases of metastatic breast cancer
with extensive immune monitoring after an unusually fa-
vorable clinical course on sequential immunoendocrine
therapy. Two of ten patients treated in a prospective study
of topical imiquimod (IMQ), a synthetic imidazoquinoline
and Toll-like receptor (TLR)-7 agonist, [13] applied to the* Correspondence: Sylvia.adams@nyumc.org
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unless otherwise stated.involved skin overlying a large primary breast cancer had
a complete and durable clinical response (CR) of all meta-
static sites during subsequent therapy. We analyzed the
longitudinal anti-tumor immunity in these two patients
and demonstrate polyfunctional T cells specific to tumor
and cancer testes (CT) antigens detected directly ex-vivo
in the peripheral blood, coinciding with CR, suggesting a
possible benchmark of beneficial immune modulation.Methods
Patients
The prospective single arm study of imiquimod in meta-
static breast cancer (clinicaltrials.gov NCT00899574, [13])
to assess response in skin metastasis was approved by the
New York University IRB and was amended to collect
follow-up blood in study patients. Patients consented to
the research and photographs provided in this publication.
Ten patients were enrolled and treated. IMQ was applied
to cutaneous areas involved by tumor for 8 weeks. While
their treated tumors did not regress on study, two patients
entered a CR on the next line regimen with the antiestro-
gen fulvestrant. As CRs to fulvestrant are infrequent (1%
in phase 3 trial) [14] and both are ongoing, we analyzedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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2 years after enrollment into the IMQ trial. PBMCs were
isolated from heparinized blood by Ficoll centrifugation
and frozen in aliquots using pooled human serum (90%)
and DMSO (10%).
Intracellular cytokine analysis of ex-vivo PBMCs
PBMCs available from pre-IMQ-treatment, post-IMQ-
treatment, and long-term follow up were thawed, washed
in complete R-10 medium supplemented with 20 IU/ml
DNase I (Roche) and cultured overnight at 37°C. The
following day, 5 million viable cells/ml were placed in
complete R-10 medium in the presence of 1 ug/ml anti-
CD28 and anti-CD49d antibodies (BD Biosciences), and
either 1 ug/ml PRAME and MAGE A3 overlapping pep-
tides (Proimmune, 15mer peptides overlapping by 11
amino acids) or control antigens (ProMix CEF and MOG
peptide pool; ProImmune). A mixture of Brefeldin A and
Monensin (GolgiPlug and GolgiStop, BD Biosciences) was
added after 1 hour culture, before culturing for an add-
itional 5 hours. Samples were then washed with PBS,
stained for 20 minutes at room temperature with anti-
CD8 PerCP-Cy5.5 and anti-CD4 FITC antibodies (BD
Biosciences) and LIVE/DEAD violet (Invitrogen), washed
again with PBS, then fixed and permeabilized for 20 mi-
nutes at room temperature using Cytofix/Cytoperm solu-
tion (BD Biosciences). Samples were then washed using
Perm/Wash solution (BD Biosciences) and stained for
intracellular antigens using anti-IFN-γ AlexaFluor 700
(BioLegend), anti-TNF-α PE-Cy7, anti-IL-2 PE, anti-IL-4
APC, and anti-CD3 APC-H7 (BD Biosciences) antibodies
for 20 minutes at room temperature. Samples were washed
once with Perm/Wash solution, and acquired on a BD LSR
II flow cytometer. 7-color compensation (parallel controls
using cells singly stained for each color) and data analysis
was performed with FlowJo flow cytometry analysis
software (TreeStar). The induction or boosting of TAA-
specific T cell immunity was defined as a post-treatment or
long-term follow up value of at least 3-fold higher than
baseline that is also 3-fold or greater than parallel negative
controls (and at least 0.03).
Intracellular cytokine staining (ICS) of peripheral
lymphocytes after in vitro presensitization (IVS) were
performed by thawing PBMCs and culturing overnight
in 10% PHS/RPMI, followed by separation into CD4+,
CD8+, and CD4-CD8- (APC) fractions using Dynal
Beads (Invitrogen). Purity of CD4+ and CD8+ fractions
were 80-90% after separation. Each fraction was then
washed and resuspended in 5% PHS/RPMI containing
10 U/ml IL-2 and 10 ng/ml IL-7. APCs were pulsed with
ProMix/ProImmune peptide pool of the desired antigen
(MAGE, PRAME, Her2, Survivin, or Wt-1, 5 μg/ml) for
1 h, irradiated (3000 rads) and then co-cultured with
CD4+ or CD8+ cells (ratio of 1:1 or 1:2) in a 96-wellround-bottom plate for 14–20 days, replenishing medium
and cytokines every 2–3 days. After incubation, IVS T cell
cultures were tested for reactivity to antigens (e.g. MAGE,
PRAME) by ICS. IVS T cell cultures were harvested,
washed, and replated in 10% PHS/RPMI medium in a 96-
well V-bottom plate. Each test antigen peptide pool (1 μg/
ml) was added to its own respective test well. Control
wells containing DMSO, MOG, CEF, and PMA/Ionomycin
were also included. For all ICS cultures, plates were incu-
bated for 1 h at 37°C, after which BD GolgiPlug and
GolgiStop was added to each well and the cultures incu-
bated another 5 h. Cells were then stained for CD4 and
CD8, fixed and permeabilized with BD Cytofix/Cytoperm
solution, then washed with 1X BD Perm/Wash buffer and
stained for CD3, CD4, CD8, IL-2, TNF-α, IL-4, IFN-γ and
Live/Dead Violet. Cells were analyzed on a BD LSR II flow
cytometer using FACSDiva software. Data were analyzed
using FlowJo software (TreeStar).
Results
Patient 1 is a 49 year old premenopausal woman who
presented in September of 2009 at diagnosis with malig-
nant hypercalcemia due to diffuse bone metastases of
breast cancer. The primary tumor had replaced the en-
tire left breast and invaded the skin, pectoralis muscle
and sternum (Figure 1). Biopsy of the breast revealed a
poorly differentiated, estrogen receptor (ER)-positive, hu-
man epidermal growth factor receptor (HER)-2 negative
invasive ductal carcinoma; imaging tests confirmed widely
metastatic disease with pulmonary and osseous metastases.
After an initial course of chemotherapy with weekly
paclitaxel and bevacizumab (in addition to bisphosphonates)
which improved the patient’s symptoms, treatment was
switched to hormonal therapy with a LH-RH agonist and
tamoxifen (with continued zoledronic acid). Upon progres-
sion 5 months later (April 2010), topical IMQ was added to
all areas of involved skin. After one 8 week cycle the patient
showed stable disease locally, however, imaging revealed one
new lung metastasis, and the patient discontinued study
treatment. Systemic therapy was switched to fulvestrant, on
which the patient experienced a CR in September of 2010
including breast, skin, lung and bone lesions, which has
been ongoing > 2 years (follow-up blood draws in February
2012 and April 2012).
Immune monitoring results for patient 1 are shown in
Figure 2. Before treatment with imiquimod, no MAGE
or PRAME- specific T cells were detected in ex-vivo as-
says. After IMQ treatment, MAGE-specific T cells were
detectable at very low frequency (0.04% of CD8+),
mainly TNF-α secreting. Long-term PBMC evaluation
(in the setting of complete clinical response on fulvestrant)
revealed a sustained CD8+ Tcell response detected directly
ex-vivo to MAGE antigens (up to 0.189% of peripheral
CD8+ lymphocytes), with a significant portion producing
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Figure 1 Clinical exam photographs, imaging (CT scans and PET/CT available only at last follow-up), tumor marker (CA 27–29) and
treatment regimens according to timeline for patient 1. At initial presentation of the patient with malignant hypercalcemia in September
2009, the locally advanced breast cancer involved the overlying skin, invaded the pectoralis muscle and sternum; in addition lung metastases
were detected by imaging as well as bone metastases (not shown). Interval treatments included paclitaxel, bevacizumab, LH-RH agonist, tamoxifen,
topical imiquimod followed by fulvestrant, on which the patient experienced a complete response including breast, skin, lung and bone lesions in
September of 2010. At last follow up August 2012, patient had no clinical or radiographic evidence of disease.
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MAGE-specific T cells showed significant expansion in the
CD4+ and CD8+ compartments and confirmed polyfunc-
tionality. MAGE-specific T cells did not secrete IL-4 or IL-
2 (not shown). A CD8+ T cell response to PRAME was
seen ex-vivo at LTFU1, but was only detectable after IVS
by LTFU2. Pre-treatment samples were not available for
IVS analysis.
Patient 2 is a 50 year old premenopausal woman who
presented in August 2009 with a fungating breast mass,
involving skin and pectoralis muscle, which was histo-
logically proven to be a poorly differentiated, ER- posi-
tive and HER2-positive invasive ductal carcinoma. Imaging
demonstrated enlarged axillary and mediastinal lymph
nodes as well as adrenal metastases (Figure 3). After initial
therapy with trastuzumab and paclitaxel, including a
course of concurrent radiotherapy to the breast for local
palliation, taxane-induced neurotoxicity developed and
treatment was switched to a LH-RH agonist and tamoxifen(with continued trastuzumab). Approximately 4 months
later (March 2010), with stable disease, topical IMQ was
added to all areas of involved skin. After one 8 week
cycle the patient showed stable disease, however, she did
not proceed to a second cycle. Upon disease progression
3 months later, systemic treatment was switched to
fulvestrant (with continued trastuzumab), and she ex-
perienced a CR on this regimen in March of 2011, which
has been ongoing >2 years. Follow-up bloods were ob-
tained in April 2012.
Immune monitoring results for patient 2 are shown in
Figure 4. As there was no functional recovery of PBMC
after thawing for the pre- and post-IMQ time points,
results are only available from long-term follow-up.
MAGE-specific CD4+ T cells were detected ex-vivo
(0.1%) during long-term follow-up (in complete clinical
remission) (Figure 4B). IVS confirmed the presence of
polyfunctional CD4+ MAGE-specific T cells, as well as
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Figure 2 Patient 1 antigen-specific responses pre and post IMQ treatment. Ex-vivo MAGE and PRAME specific CD8+ (A) and CD4+ (B) T cell
responses from bulk PBMCs of Patient 1 pre and post (post treatment and long term follow up 1 and 2) IMQ treatment were evaluated by intracellular
cytokine staining for IFN-γ and TNF-α. CD8+ and CD4+ T cells were bead sorted from PBMCs collected post IMQ treatment and in vitro stimulated with
CD8 and CD4 depleted PBMCs pulsed with MAGE or PRAME OLPs for 14–20 days. MAGE or PRAME specific CD8+ (C) and CD4+ (D) T cell responses
were analyzed by intracellular cytokine staining for IFN-γ and TNF-α. Note that the flow plot for Prame looks different due to issues during acquisition
of sample with too few cells. As controls, T cells were also stimulated with MOG and CEF OLPs and PMA/Ionomycin.
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(Figure 4D). Antigen-specific T cells did not secrete IL-4
or IL-2 (not shown). No MAGE or PRAME specific
CD8+ T cells were detected ex-vivo and after in vitro
stimulation.
Non-responder patients
Among the other eight patients who were treated on the
IMQ trial, and progressed either on study or during sub-
sequent therapies, three women who consented to
follow-up blood draws died due to disease progression.
In these three women, no immune response was de-
tected to several tumor antigens including MAGE and
PRAME by ex-vivo analysis; results of a representative
patient are shown in Figure 5. Only for one of the three
patients were paired samples available to additionallyanalyze the immune response by IVS. No CD4 or CD8
T cell response to MAGE was detected after IVS (data
not shown).
Discussion
We demonstrate that two patients with metastatic breast
cancer who were treated with sequential immune-
endocrine therapy and experienced durable complete
responses had detectable antigen-specific T cells to
several tumor antigens, in particular ex-vivo measurable
MAGE A3-specific T cells. Importantly, these antigen-
specific T cells were polyfunctional (IFN-γ+, TNF-α+, IL-4-,
consistent with a Th1 profile) which has been associated
with productive immune responses to vaccines [15]. Parallel
evaluation of PBMCs of one patient from before and after
IMQ treatment revealed that, while not detectable at
Patient 2 
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Figure 3 Clinical exam photographs, imaging (PET/CT), tumor marker (CA 27–29) and treatment regimens according to timeline for
patient 2. At initial presentation of the patient in August 2009, the locally advanced breast cancer involved the overlying skin, axillary lymph
nodes and invaded the pectoralis muscle. In addition an adrenal metastasis and mediastinal lymph nodes were detected by imaging. Interval
treatments included paclitaxel, trastuzumab, LH-RH agonist, tamoxifen, topical imiquimod followed by fulvestrant, on which the patient experienced
a complete response including breast, lymph nodes and adrenal lesions in October of 2011. At last follow up May 2014, patient had no clinical or
radiographic evidence of disease.
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the skin induced low frequency MAGE-A3-specific CD8+
T cells which were significantly expanded during subse-
quent endocrine therapy. In contrast, three patients who
died due to subsequent progression did not have detectable
MAGE A3-specific T cells.
Although IMQ can induce both CD4 and CD8 T cell
responses [16,17], the induction of CD4 versus CD8 T
cell responses in these two patients may be partly attrib-
utable to the differential effects of prior chemotherapy/
bevacizumab on the function of antigen presenting cells
[18] as well as differences in the complex tumor micro-
environment [19]. Regardless, both CD4 and CD8 T cell
responses are necessary for induction of productive im-
mune response against tumors [20].
Long-term durable responses are rare in metastatic can-
cer. However, immunotherapy trials followed by chemo-or endocrine therapy have demonstrated in some patients
an unexpectedly high response rates and prolonged
progression-free survival [7-9]. Patients who respond
to immunotherapy or sequential therapies rarely have
simultaneous immune monitoring to define the magni-
tude of immune response boost, correlatives of re-
sponse and what differentiates the responders from the
non-responders, studies which are crucial to the de-
velopment of more effective therapies. One trial of
metastatic breast cancer patients demonstrated an as-
sociation of the presence of IFN-γ + tumor antigen-
reactive peripheral T cells with long-term survival
after adoptive transfer of antigen-specific T cells [21].
In this study, even with in vitro reactivation of tumor
antigen-specific T cells derived from patient bone mar-
row only 1.7% of PMBCs were antigen specific CD8
cells [22]. Vaccine studies have typically induced lower
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Figure 4 Patient 2 antigen-specific responses post IMQ treatment. Ex-vivo analysis of MAGE and PRAME specific CD8+ (A) and CD4+ (B) T
cell responses from bulk PBMCs of Patient 2 by intracellular staining for IFN-γ and TNF-α. CD8+ and CD4+ T cells were bead sorted from PBMCs
collected post IMQ treatment and in vitro stimulated with CD8 and CD4 depleted PBMCs pulsed with MAGE, PRAME, SURVIVIN, HER-2, or WT-1
OLPs for 14–21 days. Tumor antigen-specific CD8+ (C) and CD4+ (D) T cell responses were analyzed by intracellular staining for IFN-γ and TNF-α.
As controls, T cells were also stimulated with MOG and CEF OLPs and PMA/Ionomycin.
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ation with three peptides led to a level of 1 HER2-
specific T cell to 6,000 PBMCs [23]. In another HER2
vaccine study, at baseline 0.38% of CD8 cells were
HER2-specific. With serial vaccination, the maximum
expansion reached 1.8%, but levels returned to 0.45%
at 6 months (not statistically significantly increased
from baseline) [24].
In addition to HER2 and PRAME which are expressed
in 17% and 53% of breast cancers, respectively [25,26],
CT antigens have also been targets for vaccine trials and
are desirable antigens due to their restricted expression
pattern [27]. Several cancer vaccine trials of CT antigens
such as MAGE-A3 and NY-ESO-1 have demonstrated
the ability to induce cellular and humoral immune re-
sponses, especially when used with potent vaccine adju-
vants including TLR agonists [28,29]. The persistence of
vaccine-induced B and T cell memory responses yearsafter booster immunization has also been demonstrated
[28]. Consequently, the National Cancer Institute has
placed two CT antigens, MAGE-A3 and NY-ESO-1, into
the top 10 category of the Project for the Prioritization
of Cancer Antigens [30].
While studies have reported varying frequencies of CT
antigen expression in primary breast cancer [31-41], ex-
pression data are rarely available for paired samples from
the same patient experiencing distant metastases. In
melanoma and lung cancer, studies from our group and
others reported a higher expression of CT antigens in
metastatic deposits compared with primary lesions,
which suggests that these antigens are frequently ac-
quired during progression [42,43]. While robust ex-
pression data for breast cancer in primary tumors and
subsequent metastases are not available, a study using
multiple MAGE-recognizing primers (MMRPs) that
can simultaneously detect 6 MAGE-A gene subtypes
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Figure 5 Representative analysis of tumor antigen-specific responses in non-responder patient. Representative ex-vivo analysis of antigen-specific
CD8+ (A) and CD4+ (B) T cell responses from bulk PBMCs of one of three patients who also received IMQ treatment alongside Patient 1 and 2 by
intracellular staining for IFN-γ and TNF-α. As controls, T cells were also stimulated with MOG and CEF overlapping peptides and PMA/Ionomycin.
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cells in patients with breast cancer suggests that increas-
ing MAGE-A gene expression predicts for tumor progres-
sion or recurrence [44].
Our immune evaluation of long-term disease-free
breast cancer patients suggests in-situ vaccination is
achieved by application of the TLR7- agonist directly
onto tumors and subsequent endocrine therapy can
expand these responses. Furthermore, we suggest that
antigen-specific immune responses detected directly
ex-vivo during freedom of detectable disease may indi-
cate a contribution of the immune response to disease
control in metastatic breast cancer. This is particularly
plausible as the cytokine profile of these cells is simi-
lar to T cells specific to infectious agents including
CMV-responsive T cells, and unlike the profile seen in
breast cancer where the majority of preexisting cancer
antigen T cells fails to produce IFN-y [45].Strengths of this study include the availability of cryo-
preserved PBMCs from various time points, which
allowed an immune analysis from two breast cancer pa-
tients with rare durable responses, and treatment with
IMQ on a clinical trial with prospective follow up for
2 years and the willingness of the two long-term re-
sponders as well as several patients with disease progres-
sion (controls) to donate blood samples. Antigens for
immune monitoring were chosen based on their use in
vaccine trials and expression in breast cancer. Limita-
tions of our study are that we were unable to test the pa-
tients’ tumor expression for MAGE and PRAME,
although HER2 expression was demonstrated by stand-
ard immunohistochemistry in the primary tumor of the
patient who developed anti-HER2 T cell responses.
MAGE-A3 antibodies were not detected in any of the
patients at any time point (data not shown), HER2 and
PRAME antibodies were not measured. Furthermore,
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tumor cytotoxicity of these T cells in vitro. In addition,
the lack of the pre-treatment samples for patient 2 limits
the interpretation of our findings.
Conclusion
In summary, we demonstrate that IT-induced antigen-
specific T cells can be expanded by subsequent endocrine
therapy, co-secrete IFN-γ and TNF-α and correlated with
complete and durable responses. This suggests that the
induction and boosting of TAA-specific T cells de-
tected directly ex-vivo is a benchmark for true clinical
benefit in patients with metastatic breast cancer.
Therefore, biomarkers in the blood may be appropriate
surrogates for predicting clinical responsiveness in the
future.
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